Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pelthos Therapeutics (PTHS) Research & Development (2024 - 2025)

Pelthos Therapeutics has reported Research & Development over the past 2 years, most recently at $374000.0 for Q4 2025.

  • Quarterly results put Research & Development at $374000.0 for Q4 2025, up 31.23% from a year ago — trailing twelve months through Dec 2025 was $1.2 million (up 4.12% YoY), and the annual figure for FY2025 was $1.2 million, up 4.16%.
  • Research & Development for Q4 2025 was $374000.0 at Pelthos Therapeutics, up from $145000.0 in the prior quarter.
  • Over the last five years, Research & Development for PTHS hit a ceiling of $514814.0 in Q2 2025 and a floor of $12955.0 in Q2 2024.